Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: Relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response

Psychopharmacology

Volumn 181, Issue 4, 2005, Pages 751-760

  Nikisch, Georg ^a   Mathé, Aleksander A ^c   Czernik, Adelheid ^a   Thiele, Jutta ^a   Bohner, Jürgen ^a   Eap, Chin B ^b   Ågren, Hans ^c   Baumann, Pierre ^b  

^a KLINIKUM FULDA   (Germany)

^b DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACTH; Clinical response; Cortisol; CSF; Dexamethasone suppression CRH stimulation test; Hypothalamic pituitary adrenal axis; Major depression; R S citalopram

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; MIRTAZAPINE; PAROXETINE; PLACEBO; REBOXETINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEXAMETHASONE SUPPRESSION TEST; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HORMONAL REGULATION; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; LINEAR REGRESSION ANALYSIS; MAJOR DEPRESSION; MALE; MULTIPLE REGRESSION; PREDICTION; PRIORITY JOURNAL; STRESS; SYMPTOMATOLOGY;

EID: 25844518335     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0034-3     Document Type: Article

References (57)

1. Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ (2001) Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 155:323-326
2. Barden N, Reul JM, Holsboer F (1995) Do antidepressants stabilize mood through actions and the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 18:6-11
3. Bhagwagar Z, Whale R, Cowen PJ (2002) State and trait abnormalities in serotonin function in major depression. Br J Psychiatr 180:24-28
4. Bowie PC, Beaini AY (1985) Normalization of the dexamethasone suppression test: a correlate of clinical improvement in primary depressives. Br J Psychiatr 147:30-35
5. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ Jr (1992) The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin- releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 572:117-125
6. Budziszewska B, Siwanowicz J, Przegalinski E (1994) The effect of chronic treatment with antidepressant drugs on the corticosteroid receptor levels in the rat hippocampus. Pol J Pharmacol 46:147-152
7. De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA (1993) Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatr 150:656-657
8. Ehnvall A, Sjögren M, Zachrisson O, Ågren H (2004) HPA axis activation determined by the CRH challenge test in patients with few versus multiple episodes of treatment-refractory depression. Eur Arch Psychiatry Clin Neurosi 264:349-355
9. El Khoury A, Mørk A, Mathé AA (2004) Effects of early maternal separation in a rat model of depression are alleviated by prophylactic escitalopram treatment. Nord J Psychiatry 58:93
10. El Khoury A, Gruber SHM, Mørk A, Mathé AA (2005) Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. Prog Neuro-psychopharmacol Biol Psychiatry (in press)
11. Gerken A, Maier W, Holsboer F (1985) Weekly monitoring of dexamethasone suppression response in depression: its relationship to change of body weight and psychopathology. Psychoneuroendocrinology 10:261-271
12. Greden F, Gardner R, King D, Grunhaus L, Carroll J, Kronfol Z (1983) Dexamethasone suppression test in antidepressant treatment of melancholia. Arch Gen Psychiatry 40:493-500
13. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
14. Heuser IJE, Yassouridis A, Holsboer F (1994) The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28:341-356
15. Heuser IJE, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M et al (1996) Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 153:93-99
16. Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501
17. Holsboer F, Barden N (1996) Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev 17:187-205
18. Holsboer F, Liebl R, Hofschuster E (1982) Repeated dexamethasone suppression test during depressive illness. Normalization of test result compared with clinical improvement. J Affect Disord 4:93-101
19. Holsboer F, Gerken A, Stalla GK, Muller OA (1985) ACTH, cortisol and corticosterone output after ovine corticotrophin-releasing factor challenge during depression and after recovery. Biol Psychiatry 20:276-286
20. Holsboer-Trachsler E, Stohler R, Hatzinger M (1991) Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res 38:163-171
21. Husum H, Mikkelsen JD, Hogg S, Mathé AA, Mørk A (2000) Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 39:1463-1473
22. Inder WJ, Prickett CR, Mulder RT, Donald RA, Joyce PR (2001) Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology 156:73-78
23. Jensen JB, Jessop DS, Harbuz MS, Mork ASC, Mikkelsen JD (1999) Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. J Neuroendocrinol 11:465-471
24. Jiménez PA, Salmi P, Ahlenius S, Mathé AA (2000) Neuropeptide Y in brains of the Flinders sensitive line rat, a model of depression. Effects of electroconvulsive stimuli and D-amphetamine on peptide concentrations and locomotion. Behav Brain Res 111:115-123
25. Kapitany T, Schindl M, Schindler SD, Heßelmann B, Füreder T, Barnas C et al (1999) The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 88:75-88
26. Kirschbaum C, Kudielka BM, Gaab J, Schommer NC, Hellhammer DH (1999) Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. Psychosom Med 61:154-162
27. Kosel M, Eap CB, Amey M, Baumann P (1998) Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. J Chromatogr B 719:234-238
28. Linkowski P, Mendlewicz J, Le Clerc R, Brasseur M, Hubain P, Goldstein J et al (1985) The 24-hour profile of ACTH and cortisol in major depressive illness. J Clin Endocrinol Metab 61:429-438
29. Mathé AA (1999) Neuropeptides and electroconvulsive treatment. J ECT 15:60-75
30. Mathé AA, Jousisto-Hanson J, Stenfors C, Theodorsson E (1990) Effect of lithium on tachykinins, calcitonin gene-related peptide, and neuropeptide Y in rat brain. J Neurosci Res 26:233-237
31. Mathé AA, Rudorfer MV, Stenfors C, Manji HK, Potter WC, Theodorsson E (1996) Effects of electroconvulsive treatment on somatostatin, neuropeptide Y, endothelin and neurokinin A concentrations in cerebrospinal fluid of depressed patients. Depression 3:250-256
32. Meltzer HY, Simonovic M, Sturgeon RD, Fang VS (1981) Effect of antidepressants, lithium and electroconvulsive treatment on rat serum prolactin levels. Acta Psychiatr Scand 63:100-121
33. Modell S, Lauer CJ, Schreiber W, Huber J, Krieg JC, Holsboer F (1998) Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 18:253-262
34. Moncek F, Duncko R, Jezova D (2003) Repeated citalopram treatment but not stress exposure attenuates hypothalamic-pituitary-adrenocortical axis response to acute citalopram injection. Life Sci 72:1353-1365
35. Mørk A, Kreilgaard M, Sanchez C (2003) The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45:167-173
36. Nemeroff CB, Widerlov E, Bisette G, Walleus H, Karlsson I, Eklund K et al (1984) Elevated concentrations of CSF corticotropin releasing factor-like immunoreactivity in depressed patients. Science 226:1342-1344
37. Nikisch G, Mathé AA, Czernik A, Eap CB, Jiménez-Vasquez P, Brawand-Amey M et al (2004) Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid (CSF) of depressive patients: relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol 24:283-290
38. Nikisch G, Ågren H, Eap CB, Czernik A, Baumann P, Mathé AA (2005) Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol (in press):1-8
39. Okugawa G, Omori K, Suzukawa J, Fujiseki Y, Kinoshita T, Inagaki C (1999) Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurons. J Neuroendocrinol 11:887-895
40. Pariante CM, Miller AH (2001) Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49:391-404
41. Pariante CM, Papadopoulos AS, Poon L, Cleare AJ, Checkley SA, English J et al (2004) Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology 177:200-206
42. Peiffer A, Veilleux S, Barden N (1991) Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 16:505-515
43. Pepin MC, Beaulieu S, Barden N (1989) Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Mol Brain Res 6:77-83
44. Pepin MC, Govidan MV, Barden N (1992) Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol Pharmacol 41:1016-1022
45. Ratka A, Sutanto W, Bloemers M, De Kloet ER (1989) On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 50:117-123
46. Rinne T, de Kloet ER, Wouters L, Goekoop JG, de Rijk RH, van den Brink W (2003) Fluvoxamine reduces responsiveness of HPA axis in adult female BPD patients with history of sustained childhood abuse. Neuropsychopharmacology 28:126-132
47. Rochat B, Amey M, van Gelderen H, Testa B, Baumann P (1995) Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Chirality 7:389-395
48. Rowe W, Steverman A, Walker M, Sharma S, Barden N, Seckl JR (1997) Antidepressants restore hypothalamic-pituitary-adrenal feedback function in aged, cognitively-impaired rats. Neuobiol Aging 18:527-533
49. Sanchez C (2003) R-citalopram attenuates anoxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur J Pharmacol 464:155-158
50. Schüle C, Baghai T, Zwanzger P, Ella R, Eser D, Padberg F et al (2003) Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology 166:271-275
51. Schweitzer I, Maguire KP, Gee AH, Tiller JW, Biddle N, Davies B (1987) Prediction of outcome in depressed patients by weekly monitoring with the dexamethasone suppression test. Br J Psychiatry 151:780-784
52. Seckl JR, Fink G (1992) Antidepressants increase glucocorticoid and mineralcorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 55:621-626
53. Seifritz E, Baumann P, Müller MJ, Annen O, Amey M, Hemmeter U et al (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. Neuropsychopharmacology 14:253-263
54. Steckler T, Holsboer F, Reul JM (1999) Glucocorticoids and depression. Baillieres Best Pract Res Clin Endocrinol Metab 13:597-614
55. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M (1997) SKID-I. Strukturiertes Klinisches Interview für DSM.IV. Achse I: Psychische Störungen. Hofgrefe, Göttingen, Germany
56. Yau JL, Noble J, Hibberd C, Seckl JR (2001) Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neurosci Lett 306:161-164
57. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M (2001) Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiat Res 35:83-94